The House this week gave the green light to a bipartisan drug pricing bill that targets practices by pharmaceutical companies that ultimately lead to higher costs for taxpayers.
According to a Beckers Hospital Review report, the bill would give the Department of Health and Human Services that authority to reclassify a drug, gather incorrect rebate payments and penalize drugmakers that intentionally misclassify a drug to pay out lower rebates to Medicaid.
The bill was introduced by Sens. Chuck Grassley and Ron Wyden.
“While families struggle to afford medicines like EpiPen, drugmakers are buys manipulating the system to squeeze taxpayers even more,” Wyden told The Hill. “This bipartisan bill will crack down on big pharma’s games and help prevent them from taking advantage of Medicaid, a program meant to protect the most vulnerable.”
To read the full report, click here.